MCID: MTS004
MIFTS: 19

Metastatic Insulinoma malady

Categories: Rare diseases

Aliases & Classifications for Metastatic Insulinoma

Aliases & Descriptions for Metastatic Insulinoma:

Name: Metastatic Insulinoma 50

Classifications:



Summaries for Metastatic Insulinoma

MalaCards based summary : Metastatic Insulinoma is related to insulinoma and hepatitis. The drugs pancreatic polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include brain, pancreas and pancreatic islet.

Related Diseases for Metastatic Insulinoma

Diseases related to Metastatic Insulinoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 insulinoma 10.4
2 hepatitis 9.9
3 pancreatitis 9.8
4 hypoglycemia 9.8
5 glucagonoma 9.8
6 islet cell tumor 9.6
7 familial hypocalciuric hypercalcemia 9.6
8 neuroendocrine tumor 9.6
9 pancreatic islet cell tumors 9.6
10 pancreatic neuroendocrine tumor 9.6

Graphical network of the top 20 diseases related to Metastatic Insulinoma:



Diseases related to Metastatic Insulinoma

Symptoms & Phenotypes for Metastatic Insulinoma

Drugs & Therapeutics for Metastatic Insulinoma

Drugs for Metastatic Insulinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Analgesics Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Narcotics Phase 3
18 Analgesics, Opioid Phase 3
19 Anesthetics Phase 3
20 Anesthetics, General Phase 3
21 Anesthetics, Intravenous Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Central Nervous System Depressants Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
28
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
29
Melphalan Approved Phase 2 148-82-3 4053 460612
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
33
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
34
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
35
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
36
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
37
Streptozocin Approved Phase 2 18883-66-4 29327
38
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
39
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
40
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
41
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
42
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
46
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
47
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194
48 Topoisomerase Inhibitors Phase 2
49 Anti-Bacterial Agents Phase 2,Phase 1
50 Antibiotics, Antitubercular Phase 2,Phase 1

Interventional clinical trials:

(show all 31)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
4 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
5 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
6 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2
7 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
8 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
9 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
10 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
11 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
12 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
13 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2
14 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2
15 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
16 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2
17 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2
18 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
19 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2
20 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
21 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
22 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
23 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1
24 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
25 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
26 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
27 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
28 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
29 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
30 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Unknown status NCT00730483
31 18F-FDOPA PET in Neuroendocrine Tumours Available NCT02431715

Search NIH Clinical Center for Metastatic Insulinoma

Genetic Tests for Metastatic Insulinoma

Anatomical Context for Metastatic Insulinoma

MalaCards organs/tissues related to Metastatic Insulinoma:

39
Brain, Pancreas, Pancreatic Islet

Publications for Metastatic Insulinoma

Articles related to Metastatic Insulinoma:

(show all 35)
id Title Authors Year
1
Endoscopic Ultrasound-Guided Ethanol Ablation for Control of Local-Regional Metastatic Insulinoma. ( 28187109 )
2017
2
Focal hepatic glycogenosis associated with metastatic insulinoma presenting as mass lesions. ( 26627264 )
2016
3
Metastatic insulinoma: current molecular and cytotoxic therapeutic approaches for metastatic well-differentiated panNETs. ( 25691605 )
2015
4
Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol. ( 26562579 )
2015
5
Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. ( 24512490 )
2014
6
Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature. ( 26425568 )
2013
7
Prolonged survival in an aged Labrador retriever with a metastatic insulinoma. ( 23325593 )
2013
8
Metastatic insulinoma managed with radiolabeled somatostatin analog. ( 24455330 )
2013
9
Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. ( 23573816 )
2013
10
Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. ( 23392213 )
2013
11
Everolimus Dramatically Improves Glycemic Control in Unresectable Metastatic Insulinoma: A Case Report. ( 24367043 )
2013
12
Nocardia brain abscess in a patient treated with everolimus for a metastatic insulinoma. ( 23182991 )
2013
13
Amelioration of hypoglycemia with octreotide therapy in metastatic insulinoma with positive octreotide scan. ( 21160385 )
2011
14
Metastatic insulinoma - prolonged survival after multimodal approach. ( 21804467 )
2011
15
Metastatic insulinoma in a patient with type 2 diabetes mellitus: case report and review of the literature. ( 21331288 )
2011
16
Insulinoma cell calcium-sensing receptor influences insulin secretion in a case with concurrent familial hypocalciuric hypercalcemia and malignant metastatic insulinoma. ( 18430790 )
2008
17
Focal hepatic steatosis surrounding a metastatic insulinoma. ( 18067643 )
2008
18
Use of a continuous glucose monitor in the management of inoperable metastatic insulinoma: a case report. ( 18996817 )
2008
19
Metastatic insulinoma in an adult patient with underlying nesidioblastosis. ( 17646729 )
2007
20
Malignant metastatic insulinoma-postoperative treatment and follow-up. ( 15880279 )
2005
21
Metastatic insulinoma and glucagonoma from the pancreas responsible for specific peritumoral patterns of hepatic steatosis secondary to local effects of insulin and glucagon on hepatocytes. ( 16247938 )
2005
22
Metastatic insulinoma: case report and review of the literature. ( 14982275 )
2004
23
Role of hepatic arterial embolisation in the treatment for metastatic insulinoma. Report of two cases and review of the literature. ( 9489120 )
1997
24
Multiple genetic alterations in malignant metastatic insulinomas. ( 8568594 )
1995
25
Efficacy of the combination of carboplatin and cyclophosphamide in the treatment of metastatic insulinoma. ( 1422889 )
1992
26
Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide. ( 2894965 )
1988
27
Forced diuresis to reduce nephrotoxicity of streptozotocin in the treatment of advanced metastatic insulinoma. ( 3034373 )
1987
28
Metastatic insulinoma with long survival and glucagonoma syndrome. ( 6318634 )
1984
29
Malignant metastatic insulinoma treated with streptozotocin. ( 170028 )
1975
30
Letter: Phenytoin in metastatic insulinoma. ( 171459 )
1975
31
Streptozotocin and metastatic insulinoma. ( 4324025 )
1971
32
Notes on streptozotocin in metastatic insulinoma. ( 4329781 )
1971
33
Metastatic insulinoma treated with streptozotocin. ( 4324022 )
1971
34
Streptozotocin therapy for metastatic insulinoma. ( 4319181 )
1970
35
Streptozotocin for metastatic insulinoma. ( 4319193 )
1970

Variations for Metastatic Insulinoma

Expression for Metastatic Insulinoma

Search GEO for disease gene expression data for Metastatic Insulinoma.

Pathways for Metastatic Insulinoma

GO Terms for Metastatic Insulinoma

Sources for Metastatic Insulinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....